Peringatan Keamanan

Data regarding acute overdoses of glucocorticoids are rare.L11815,L11818,L11821 Overdoses of clobetasol propionate can lead to reversible HPA axis suppression and glucocorticoid insufficiency.L11833 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.A188405 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.A188405

Clobetasol propionate

DB01013

small molecule approved

Deskripsi

Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.L11815 It has demonstrated superior activity compared to fluocinonideA190963 and was first described in the literature in 1974.A190936

Clobetasol Propionate was granted FDA approval on 27 December 1985.L11809

Struktur Molekul 2D

Berat 466.97
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Data regarding the half life of clobetasol propionate are not readily available.[A190957]
Volume Distribusi Data regarding the volume of distribution of clobetasole propionate are not readily available.[L11815,L11818,L11821,L11824,L11827,L11833]
Klirens (Clearance) Data regarding the clearance of clobetasol propionate are not readily available.[A190957]

Absorpsi

Twice daily application of clobetasol foam leads to a Cmax of 59±36pg/mL with a Tmax of 5 hours.L11815 Clobetasol cream showed an increase in clobetasol concentrations from 50.7±96.0pg/mL to 56.3±104.7pg/mL.L11821

Metabolisme

The metabolism of clobetasol propionate is not well studied but it does induce metabolic enzymes, even when delivered topically.A190942 The metabolism of clobetasol propionate is predicted to follow similar metabolic pathways to other corticosteroids including the addition of oxygen, hydrogen, glucuronides, and sulfates to form water soluble metabolites.L11833

Rute Eliminasi

Corticosteroids are eliminated predominantly in the urine.A187436

Interaksi Obat

1170 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Clobetasol propionate.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clobetasol propionate.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Clobetasol propionate.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clobetasol propionate.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clobetasol propionate.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Clobetasol propionate.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Clobetasol propionate.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Clobetasol propionate.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Clobetasol propionate.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol propionate.
Pegaspargase The serum concentration of Clobetasol propionate can be increased when it is combined with Pegaspargase.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Clobetasol propionate.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clobetasol propionate.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clobetasol propionate.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Clobetasol propionate.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Clobetasol propionate.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Clobetasol propionate.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol propionate.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Clobetasol propionate.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clobetasol propionate.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Clobetasol propionate.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Clobetasol propionate.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clobetasol propionate.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clobetasol propionate.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Clobetasol propionate.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clobetasol propionate.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Clobetasol propionate.
Cladribine Clobetasol propionate may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Clobetasol propionate.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Clobetasol propionate.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Clobetasol propionate.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Clobetasol propionate.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Clobetasol propionate.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Clobetasol propionate.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Clobetasol propionate.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Clobetasol propionate.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Clobetasol propionate.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clobetasol propionate.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Clobetasol propionate.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Clobetasol propionate.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Clobetasol propionate.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Clobetasol propionate.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Clobetasol propionate.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Clobetasol propionate.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Clobetasol propionate.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clobetasol propionate.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Clobetasol propionate.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Clobetasol propionate.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clobetasol propionate.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clobetasol propionate.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clobetasol propionate.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Clobetasol propionate.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clobetasol propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Clobetasol propionate.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Clobetasol propionate.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Clobetasol propionate.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Clobetasol propionate.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Clobetasol propionate.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Clobetasol propionate.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Clobetasol propionate.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol propionate.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Clobetasol propionate.
Tretinoin The metabolism of Tretinoin can be increased when combined with Clobetasol propionate.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Clobetasol propionate.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Clobetasol propionate.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Clobetasol propionate.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Clobetasol propionate.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Clobetasol propionate.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Clobetasol propionate.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Clobetasol propionate.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Clobetasol propionate.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Clobetasol propionate.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Clobetasol propionate.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Clobetasol propionate.
Mycophenolic acid The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Melphalan.
Fluocinonide The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fluocinonide.
Fludarabine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Estramustine.
Mitoxantrone The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Lomustine.
Budesonide The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Budesonide.
Dexamethasone The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Dexamethasone.
Eculizumab The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nelarabine.
Abatacept The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Abatacept.
Corticotropin The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Corticotropin.
Cortisone acetate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cortisone acetate.
Paramethasone The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Paramethasone.
Ciclesonide The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ciclesonide.

Target Protein

Glucocorticoid receptor NR3C1
Annexin A1 ANXA1
Mineralocorticoid receptor NR3C2

Referensi & Sumber

Synthesis reference: Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.
Artikel (PubMed)
  • PMID: 4594577
    Sparkes CG, Wilson L: The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial. Br J Dermatol. 1974 Feb;90(2):197-203. doi: 10.1111/j.1365-2133.1974.tb06385.x.
  • PMID: 6610079
    Finnen MJ, Herdman ML, Shuster S: Induction of drug metabolising enzymes in the skin by topical steroids. J Steroid Biochem. 1984 May;20(5):1169-73. doi: 10.1016/0022-4731(84)90362-5.
  • PMID: 6851236
    Hehir M, Du Vivier A, Eilon L, Danie MJ, Shenoy EV: Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol. 1983 Mar;8(2):143-51. doi: 10.1111/j.1365-2230.1983.tb01758.x.
  • PMID: 3902682
    Jegasothy B, Jacobson C, Levine N, Millikan L, Olsen E, Pinnell S, Cole G, Weinstein G, Porter M: Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol. 1985 Sep;24(7):461-5. doi: 10.1111/j.1365-4362.1985.tb05821.x.
  • PMID: 30285357
    Yasir M, Sonthalia S: Corticosteroid Adverse Effects .
  • PMID: 23300763
    Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26.
  • PMID: 15634032
    Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.
  • PMID: 24347992
    Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975.

Contoh Produk & Brand

Produk: 319 • International brands: 4
Produk
  • Alti-clobetasol Propionate Cream 0.05%
    Cream • .05 % • Topical • Canada • Generic • Approved
  • Alti-clobetasol Propionate Ont 0.05%
    Ointment • .05 % • Topical • Canada • Generic • Approved
  • Alti-clobetasol Propionate Scalp Application 0.05%
    Liquid • .05 % • Topical • Canada • Generic • Approved
  • Apo-clobetasol Spray
    Spray • 0.05 % w/w • Topical • Canada • Generic • Approved
  • Calcipotriene 0.005% / Clobetasol Propionate 0.05%
    Solution • - • Topical • US
  • Ciclopirox 1% / Clobetasol Propionate 0.05%
    Shampoo • - • Topical • US
  • Ciclopirox Olamine 0.77% / Clobetasol Propionate 0.05% / Salicylic Acid 3%.
    Shampoo • - • Topical • US
  • Clobeta
    Kit • - • Topical • US • Generic • Approved
Menampilkan 8 dari 319 produk.
International Brands
  • Clobesol — GlaxoSmithKline
  • Dermovate — GlaxoSmithKline
  • Embeline — Hi-Tech
  • Embeline E — Hi-Tech

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul